{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:34Z","timestamp":1793324794214,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200230"],"award-info":[{"award-number":["82200230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470202"],"award-info":[{"award-number":["82470202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["UHB11543"],"award-info":[{"award-number":["UHB11543"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-051"],"award-info":[{"award-number":["2022-PUMCH-C-051"]}]},{"name":"Post-Marketing Clinical Research Special Program for Innovative Drugs","award":["WKZX2024CX105204"],"award-info":[{"award-number":["WKZX2024CX105204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06716-0","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T02:15:24Z","timestamp":1762568124000},"page":"5677-5683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of venetoclax in the treatment of relapsed\/refractory light-chain amyloidosis"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9123-393X","authenticated-orcid":false,"given":"Xin-yi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-ni","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"6716_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"6716_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ajh.27179","volume":"99","author":"R Chakraborty","year":"2024","unstructured":"Chakraborty R, Bhutani D, Mapara M et al (2024) Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study. Am J Hematol 99:477\u2013479. https:\/\/doi.org\/10.1002\/ajh.27179","journal-title":"Am J Hematol"},{"key":"6716_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","volume":"38","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Gertz MA, Muchtar E et al (2024) Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 38:1423\u20131426. https:\/\/doi.org\/10.1038\/s41375-024-02243-5","journal-title":"Leukemia"},{"key":"6716_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz MA (2024) Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol 99:309\u2013324. https:\/\/doi.org\/10.1002\/ajh.27177","journal-title":"Am J Hematol"},{"key":"6716_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood-2019-126094","volume":"134","author":"S Harrison","year":"2019","unstructured":"Harrison S, Cavo M, De La Rubia J et al (2019) T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with Relapsed\/Refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood 134:142. https:\/\/doi.org\/10.1182\/blood-2019-126094","journal-title":"Blood"},{"key":"6716_CR6","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1111\/cas.15073","volume":"112","author":"A Kitadate","year":"2021","unstructured":"Kitadate A, Terao T, Narita K et al (2021) Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci 112:3645\u20133654. https:\/\/doi.org\/10.1111\/cas.15073","journal-title":"Cancer Sci"},{"key":"6716_CR7","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.1002\/cam4.5621","volume":"12","author":"H Fishov","year":"2023","unstructured":"Fishov H, Muchtar E, Salmon-Divon M et al (2023) AL amyloidosis clonal plasma cells are regulated by micrornas and dependent on anti\u2010apoptotic BCL2 family members. Cancer Med 12:8199\u20138210. https:\/\/doi.org\/10.1002\/cam4.5621","journal-title":"Cancer Med"},{"key":"6716_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33461-z","volume":"13","author":"CS Fraser","year":"2022","unstructured":"Fraser CS, Spetz JKE, Qin X et al (2022) Exploiting endogenous and therapy-induced apoptotic vulnerabilities in Immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun 13:5789. https:\/\/doi.org\/10.1038\/s41467-022-33461-z","journal-title":"Nat Commun"},{"key":"6716_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/13506129.2024.2366806","volume":"31","author":"D Dima","year":"2024","unstructured":"Dima D, Hughes M, Orland M et al (2024) Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy. Amyloid 31:195\u2013201. https:\/\/doi.org\/10.1080\/13506129.2024.2366806","journal-title":"Amyloid"},{"key":"6716_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w","author":"P Vj","year":"2021","unstructured":"Vj P, S L, S P, et al (2021) Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-020-00397-w. 11:","journal-title":"Blood Cancer J"},{"key":"6716_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.17380","volume":"193","author":"H Pasquer","year":"2021","unstructured":"Pasquer H, Belhadj K, Dupuis J et al (2021) Venetoclax induces profound and sustained responses in patients with relapsed\/refractory light-chain amyloidosis. Br J Haematol 193:674\u2013677. https:\/\/doi.org\/10.1111\/bjh.17380","journal-title":"Br J Haematol"},{"key":"6716_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061710","volume":"15","author":"E Lebel","year":"2023","unstructured":"Lebel E, Kastritis E, Palladini G et al (2023) Venetoclax in relapse\/refractory AL amyloidosis\u2014a multicenter international retrospective real-world study. Cancers (Basel) 15:1710. https:\/\/doi.org\/10.3390\/cancers15061710","journal-title":"Cancers (Basel)"},{"key":"6716_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ajh.26207","volume":"96","author":"H Nahi","year":"2021","unstructured":"Nahi H, Kashif M, Klimkowska M et al (2021) Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). Am J Hematol 96:925\u2013933. https:\/\/doi.org\/10.1002\/ajh.26207","journal-title":"Am J Hematol"},{"key":"6716_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0321-6","volume":"10","author":"MH Sidiqi","year":"2020","unstructured":"Sidiqi MH, Al Saleh AS, Leung N et al (2020) Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 10:55. https:\/\/doi.org\/10.1038\/s41408-020-0321-6","journal-title":"Blood Cancer J"},{"key":"6716_CR15","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA et al (2012) New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"6716_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F et al (2017) Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 130:625\u2013631. https:\/\/doi.org\/10.1182\/blood-2017-02-767467","journal-title":"Blood"},{"key":"6716_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/ajh.25940","volume":"95","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Gertz MA, Lacy MQ et al (2020) Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. Am J Hematol 95:1280\u20131287. https:\/\/doi.org\/10.1002\/ajh.25940","journal-title":"Am J Hematol"},{"key":"6716_CR18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","volume":"41","author":"E Muchtar","year":"2023","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B et al (2023) Graded cardiac response criteria for patients with systemic light chain amyloidosis. J Clin Oncol 41:1393\u20131403. https:\/\/doi.org\/10.1200\/JCO.22.00643","journal-title":"J Clin Oncol"},{"key":"6716_CR19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","volume":"10","author":"E Muchtar","year":"2024","unstructured":"Muchtar E, Wisniowski B, Geyer S et al (2024) Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis. JAMA Oncol 10:1362\u20131369. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2629","journal-title":"JAMA Oncol"},{"key":"6716_CR20","doi-asserted-by":"publisher","unstructured":"Gupta VA, Barwick BG, Matulis SM et al Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. https:\/\/doi.org\/10.1182\/blood.2020007899","DOI":"10.1182\/blood.2020007899"},{"key":"6716_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.2023020276","volume":"143","author":"N Leblay","year":"2024","unstructured":"Leblay N, Ahn S, Tilmont R et al (2024) Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood 143:42\u201356. https:\/\/doi.org\/10.1182\/blood.2023020276","journal-title":"Blood"},{"key":"6716_CR22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G et al (2012) Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272\u20131277. https:\/\/doi.org\/10.3324\/haematol.2011.056176","journal-title":"Haematologica"},{"key":"6716_CR23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630\u20131642. https:\/\/doi.org\/10.1016\/S1470-2045(20)30525-8","journal-title":"Lancet Oncol"},{"key":"6716_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","volume":"33","author":"T Bochtler","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C et al (2015) Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 33:1371\u20131378. https:\/\/doi.org\/10.1200\/JCO.2014.57.4947","journal-title":"J Clin Oncol"},{"key":"6716_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204346","volume":"144","author":"K Shen","year":"2024","unstructured":"Shen K, Guan A, Wu Y et al (2024) Venetoclax plus dexamethasone as first-line treatment for t(11; 14) light-chain amyloidosis: preliminary result of a phase II prospective, multicenter, single-arm study. Blood 144:893. https:\/\/doi.org\/10.1182\/blood-2024-204346","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06716-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:30:49Z","timestamp":1764729049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06716-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6716"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06716-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and\u00a0<!--Emphasis Type='Bold' removed-->patient consent"}},{"value":"The authors declare that no commercial or financial relationships existed that could be interpreted as potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}